<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457899</url>
  </required_header>
  <id_info>
    <org_study_id>D1443L00003</org_study_id>
    <nct_id>NCT00457899</nct_id>
  </id_info>
  <brief_title>Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder</brief_title>
  <acronym>RAPID</acronym>
  <official_title>RAPID-An Open-Label Randomized, Multicenter Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immediate Release), Over 14 Days, in Acute Schizophrenia/Schizoaffective Disorder (Rapid Versus Conventional Titration)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether increasing the amount (dose) of quetiapine
      IR (immediate release formulation) more rapidly than conventional dose increases, improves
      the control of symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) - a
      psychiatric assessment scale that measures both positive and negative symptoms - in patients
      with acute schizophrenia or schizoaffective disorder.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to poor recruitment
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome variable of this study is change from baseline in total PANSS score</measure>
    <time_frame>at Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total PANSS scores</measure>
    <time_frame>on day 5 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in CGI-S and absolute CGI-I</measure>
    <time_frame>on days 5, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency and severity of adverse events; change in vital signs.</measure>
    <time_frame>assessed at each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in subscale PANSS and PANSS-EC scores</measure>
    <time_frame>on days 5, 7 and 14</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorders</condition>
  <condition>Psychotic Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine IR (Immediate Release)</intervention_name>
    <description>oral</description>
    <other_name>Seroquel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, aged 18 to 65 years, who require treatment for an acute episode of
             schizophrenia/schizoaffective disorder as judged by their doctor

        Exclusion Criteria:

          -  Significant and unstable conditions of hear, circulation, blood, liver, kidney;
             malignancies (cancer); diabetes (mellitus); history of fits or fainting. Resistance to
             antipsychotic medication. Current alcohol/drug abuse. Pregnant/breast feeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca UK Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Professor Gary Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Tydfil's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <state>Essex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surbiton</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bognor Regis</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bury St Edmunds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Crewe</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Darlington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sandbach</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warrington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.astrazeneca.com/node/emailtriage.aspx</url>
    <description>AstraZeneca Clinical Trial Information - Outside US</description>
  </link>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2007</study_first_submitted>
  <study_first_submitted_qc>April 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2007</study_first_posted>
  <last_update_submitted>November 26, 2007</last_update_submitted>
  <last_update_submitted_qc>November 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2007</last_update_posted>
  <keyword>schizophrenia</keyword>
  <keyword>schizoaffective disorder</keyword>
  <keyword>quetiapine</keyword>
  <keyword>seroquel</keyword>
  <keyword>titration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

